0001415889-23-010986.txt : 20230710 0001415889-23-010986.hdr.sgml : 20230710 20230710170436 ACCESSION NUMBER: 0001415889-23-010986 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20230629 FILED AS OF DATE: 20230710 DATE AS OF CHANGE: 20230710 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Donoghoe Nicholas CENTRAL INDEX KEY: 0001762951 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35565 FILM NUMBER: 231080464 MAIL ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AbbVie Inc. CENTRAL INDEX KEY: 0001551152 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 320375147 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 BUSINESS PHONE: (847) 932-7900 MAIL ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 3 1 form3-07102023_090731.xml X0206 3 2023-06-29 0 0001551152 AbbVie Inc. ABBV 0001762951 Donoghoe Nicholas 1 NORTH WAUKEGAN ROAD NORTH CHICAGO IL 60064 false true false false EVP, Chief Bus/Strat Officer Common Stock, $0.01 par value 58815 D Option (Right to buy) 79.02 2020-02-21 2029-02-20 Common Stock 32710 D Option (Right to buy) 93.50 2021-02-20 2030-02-19 Common Stock 72013 D Option (Right to buy) 105.92 2022-02-18 2031-02-17 Common Stock 29813 D Option (Right to buy) 144.54 2023-02-17 2032-02-16 Common Stock 21453 D Option (Right to buy) 149.62 2024-02-16 2033-02-15 Common Stock 17555 D Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 10,904 shares on 02/21/2020, as to 10,903 shares on 02/21/2021, and as to 10,903 shares on 02/21/2022. Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 24,005 shares on 02/20/2021, as to 24,004 shares on 02/20/2022, and as to 24,004 shares on 02/20/2023. Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 9,938 shares on 02/18/2022 and as to 9,938 shares on 02/18/2023, and will become exercisable as to as to 9,937 shares on 02/18/2024. Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 7,151 shares on 02/17/2023, and will become exercisable as to 7,151 shares on 02/17/2024 and as to 7,151 shares on 02/17/2025. Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option will become exercisable as to 5,852 shares on 02/16/2024, as to 5,852 shares on 02/16/2025 and as to 5,851 shares on 02/16/2026. T.O. Odutayo, attorney-in-fact for Nicholas J. Donoghoe 2023-07-10 EX-24 2 ex24-07102023_090731.htm

Exhibit 24

POWER OF ATTORNEY

The undersigned constitutes and appoints PERRY C. SIATIS, EMILY A. WEITH, and T.O. ODUTAYO, and each of them individually, as the undersigned's true and lawful attorney-in-fact and agent, with full power of substitution and re-substitution, for the undersigned and in the undersigned's name, place and stead, to prepare and sign any and all Securities and Exchange Commission ("SEC") Notices of Proposed Sales of Securities pursuant to Rule 144 under the Securities Act of 1933 on Form 144, all SEC statements on Forms 3, 4 and 5 as required under Section 16(a) of the Securities Exchange Act of 1934, including a Form ID and any other documents necessary to obtain codes and passwords necessary to make electronic filings, and any amendments or successors to such forms, and to file the same with all exhibits thereto, and other documents in connection therewith, with the SEC, granting unto said attorney-in-fact and agent full power and authority to do and perform each act and thing requisite, necessary or desirable to be done under said Rule 144 and Section 16(a), as fully for all intents and purposes as the undersigned might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent may lawfully do or cause to be done by virtue hereof.

A copy of this power of attorney shall be filed with the SEC. The authorization set forth above shall continue in full force and effect until the undersigned is no longer required to file Forms 144, 3, 4, or 5 or if earlier, until the undersigned revokes such authorization by written instructions to the attorney-in-fact.

Date: June 28, 2023

/s/ Nicholas J. Donoghoe
Signature of Reporting Person

Nicholas J. Donoghoe
Name

AbbVie Inc.
1 N. Waukegan Road
North Chicago, IL 60064